 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, May 28, 2008, 28(22):5836-5845; doi:10.1523/JNEUROSCI.4170-07.2008
Previous Article | Next Article
Behavioral/Systems/Cognitive
Activation of TRPV1 Contributes to Morphine Tolerance: Involvement of the Mitogen-Activated Protein Kinase Signaling Pathway
Yong Chen, Christian Geis, andClaudia Sommer Department of Neurology, University of Würzburg, 97080 Würzburg, Germany
Correspondence should be addressed to Dr. Yong Chen at his present address: Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill, Taylor Hall CB #7090, Chapel Hill, NC 27599-7090. Email: yong_chen{at}med.unc.edu
Tolerance to the analgesic effects of opioids occurs after their chronic administration, a pharmacological phenomenon that has been associated with the development of abnormal pain sensitivity such as hyperalgesia. In the present study, we investigated the role of TRPV1, which is crucial for the transduction of noxious chemical and thermal stimuli, in morphine tolerance and tolerance-associated thermal hyperalgesia. After chronic morphine treatment, a marked increase in TRPV1 immunoreactivity (IR) was detected in L4 dorsal root ganglion (DRG) neurons, spinal cord dorsal horn, and sciatic nerve. Real-time reverse transcription (RT)-PCR demonstrated that TRPV1 mRNA was upregulated in spinal cord and sciatic nerve but not in the DRG. Intrathecal pretreatment with SB366791 [N-(3-methoxyphenyl)-4-chlorocinnamide], a selective antagonist of TRPV1, attenuated both morphine tolerance and associated thermal hyperalgesia. Chronic morphine exposure induced increases in phosphorylation of mitogen-activated protein kinases (MAPKs), including p38 MAPK-IR, extracellular signal-regulated protein kinase (ERK)-IR, and c-Jun N-terminal kinase (JNK)-IR, in L4 DRG neurons. Intrathecal administration of the selective p38, ERK, or JNK inhibitors not only reduced morphine tolerance and associated thermal hyperalgesia but also suppressed the morphine-induced increase of TRPV1-IR in DRG neurons, spinal cord, and sciatic nerve and of mRNA levels in spinal cord and sciatic nerve. Together, we have identified a novel mechanism by which sustained morphine treatment results in tolerance and tolerance-associated thermal hyperalgesia, by regulating TRPV1 expression, in a MAPK-dependent manner. Thus, blocking TRPV1 might be a way to reduce morphine tolerance.
Key words: morphine; TRPV1; MAPK; tolerance; immunohistochemistry; RT-PCR; Western blot
Received Sept. 12, 2007; revised March 30, 2008; accepted April 22, 2008.
Correspondence should be addressed to Dr. Yong Chen at his present address: Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill, Taylor Hall CB #7090, Chapel Hill, NC 27599-7090. Email: yong_chen{at}med.unc.edu
This article has been cited by other articles:
S. Tumati, H. I. Yamamura, T. W. Vanderah, W. R. Roeske, and E. V. Varga
Sustained Morphine Treatment Augments Capsaicin-Evoked Calcitonin Gene-Related Peptide Release from Primary Sensory Neurons in a Protein Kinase A- and Raf-1-Dependent Manner
J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 810 - 817.
[Abstract] [Full Text] [PDF]
Z. Wang, W. Ma, J.-G. Chabot, and R. Quirion
Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia
FASEB J, August 1, 2009; 23(8): 2576 - 2586.
[Abstract] [Full Text] [PDF]
Y. Niiyama, T. Kawamata, J. Yamamoto, S. Furuse, and A. Namiki
SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain
Br. J. Anaesth., February 1, 2009; 102(2): 251 - 258.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|